The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Résumé: La prise en charge des patientes atteintes d’un cancer du sein métastatique devient de plus en plus complexe. L’évolution actuelle des traitements adjuvants est en train demodifier l’étendue de l’arsenal thérapeutique disponible une fois le stade métastatique atteint. En l’absence de consensus, cet article a pour objectif de présenter les options thérapeutiques à notre disposition en termes...
Résumé: Les cancers du sein HER2 positifs représentent environ 20 % des cancers du sein. Ils ont été initialement caractérisés par leur mauvais pronostic et notamment la courte survie sans récidive et le profilé volutif métastatique. Le trastuzumab est le premier anticorps monoclonal dirigé contre HER2 ayant démontré un impact majeur sur la survie en situation adjuvante. Malgré cela les modalités...
Trastuzumab has been widely studied in combination with chemotherapy. Efficacy and safety data have been established for several combination regimens. Because trastuzumab in combination with chemotherapy has been shown to improve survival for women with HER2-overexpressing metastatic breast cancer when compared to treatment with chemotherapy alone, the use of combination therapy is the preferred initial...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.